BiotechTube

Furmonertinib

Phase 1/2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adenocarcinoma of Lung

Conditions

Adenocarcinoma of Lung

Trial Timeline

Oct 1, 2021 → Sep 1, 2024

NCT ID
NCT05079022

About Furmonertinib

Furmonertinib is a phase 1/2 stage product being developed by Burning Rock Biotech for Adenocarcinoma of Lung. The current trial status is unknown. This product is registered under clinical trial identifier NCT05079022. Target conditions include Adenocarcinoma of Lung.

What happened to similar drugs?

1 of 20 similar drugs in Adenocarcinoma of Lung were approved

Approved (1) Terminated (0) Active (19)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
🔄Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
🔄CT-P16 + AvastinCelltrionPhase 3
🔄Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
🔄zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
🔄zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
9
Activity
4
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05079022Phase 1/2UNKNOWN

Competing Products

20 competing products in Adenocarcinoma of Lung

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
32
RamucirumabEli LillyPhase 1/2
32
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
BA3182BioAtlaPhase 1
26
Ramucirumab (IMC-1121B ) + PaclitaxelEli LillyPhase 1
29
CT-P16 + AvastinCelltrionPhase 3
40
Bevacizumab + Capecitabine + Cisplatin + Placebo + 5-fluorouracilChugai PharmaceuticalPhase 3
40
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
44
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
42
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
DS-8201aDaiichi SankyoPhase 1
29
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
39
EnzalutamideAstellas PharmaPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44